Increased expression of β-galactoside α2,6-sialyltransferase I (ST6GAL1), an enzyme generated α2,6-sialylated lactosamine, is often associated with invasive phenotype and poor prognosis in several cancers, including colon, stomach, and ovarian cancers (24). This evidence concerns the gene ST6GAL1 and cancer.